Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action

Jinling Chen, Yuejin Liang, Panpan Yi, Lanman Xu, Hal K. Hawkins, Shannan Rossi, Lynn Soong, Jiyang Cai, Ramkumar Menon, Jiaren Sun

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Zika virus (ZIKV) infection during pregnancy in humans results in intrauterine growth restriction, spontaneous abortion, and microcephaly. Here, we found that fetus-derived type I interferon (IFN-I) signaling can enhance anti-ZIKV responses and provide clinical benefits to the fetus. Because IFN-λ shares signaling cascades and antiviral functions with IFN-I, we investigated the in vivo effects of IFN-λ in ZIKV-infected pregnant mice. IFN-λ administration during mid-pregnancy reduced ZIKV burden in maternal and fetal organs and alleviated placental injuries and fetal demise. In addition, prophylactic and therapeutic treatment of IFN-λ1 in a human trophoblast line, as well as in primary human amniotic epithelial cells, greatly reduced the ZIKV burden. Our data highlight IFN-λ1 as a potential therapeutic useful for women at risk for congenital Zika disease. Chen et al. find that fetus-derived IFN-I signaling contributes to anti-ZIKV responses. IFN-λ administration during mid-pregnancy promotes host defense and reduces disease severity. IFN-λ1 treatment upregulates MX1 expression and establishes an antiviral state, leading to reduced ZIKV replication or elimination.

Original languageEnglish (US)
Pages (from-to)1588-1599
Number of pages12
JournalCell Reports
Volume21
Issue number6
DOIs
StatePublished - Nov 7 2017

Fingerprint

Viruses
Interferons
Mothers
Infection
Fetus
Pregnancy
Antiviral Agents
Microcephaly
Interferon Type I
Fetal Death
Trophoblasts
Spontaneous Abortion
Therapeutics
Virus Replication
Zika Virus
Up-Regulation
Epithelial Cells
Wounds and Injuries
Growth

Keywords

  • animal model
  • antiviral
  • congenital infection
  • gestational stage
  • human pregnancy
  • interferon-λ
  • Zika virus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action. / Chen, Jinling; Liang, Yuejin; Yi, Panpan; Xu, Lanman; Hawkins, Hal K.; Rossi, Shannan; Soong, Lynn; Cai, Jiyang; Menon, Ramkumar; Sun, Jiaren.

In: Cell Reports, Vol. 21, No. 6, 07.11.2017, p. 1588-1599.

Research output: Contribution to journalArticle

Chen, Jinling ; Liang, Yuejin ; Yi, Panpan ; Xu, Lanman ; Hawkins, Hal K. ; Rossi, Shannan ; Soong, Lynn ; Cai, Jiyang ; Menon, Ramkumar ; Sun, Jiaren. / Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action. In: Cell Reports. 2017 ; Vol. 21, No. 6. pp. 1588-1599.
@article{ca3cd55a93624e82a6909ca847a32408,
title = "Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action",
abstract = "Zika virus (ZIKV) infection during pregnancy in humans results in intrauterine growth restriction, spontaneous abortion, and microcephaly. Here, we found that fetus-derived type I interferon (IFN-I) signaling can enhance anti-ZIKV responses and provide clinical benefits to the fetus. Because IFN-λ shares signaling cascades and antiviral functions with IFN-I, we investigated the in vivo effects of IFN-λ in ZIKV-infected pregnant mice. IFN-λ administration during mid-pregnancy reduced ZIKV burden in maternal and fetal organs and alleviated placental injuries and fetal demise. In addition, prophylactic and therapeutic treatment of IFN-λ1 in a human trophoblast line, as well as in primary human amniotic epithelial cells, greatly reduced the ZIKV burden. Our data highlight IFN-λ1 as a potential therapeutic useful for women at risk for congenital Zika disease. Chen et al. find that fetus-derived IFN-I signaling contributes to anti-ZIKV responses. IFN-λ administration during mid-pregnancy promotes host defense and reduces disease severity. IFN-λ1 treatment upregulates MX1 expression and establishes an antiviral state, leading to reduced ZIKV replication or elimination.",
keywords = "animal model, antiviral, congenital infection, gestational stage, human pregnancy, interferon-λ, Zika virus",
author = "Jinling Chen and Yuejin Liang and Panpan Yi and Lanman Xu and Hawkins, {Hal K.} and Shannan Rossi and Lynn Soong and Jiyang Cai and Ramkumar Menon and Jiaren Sun",
year = "2017",
month = "11",
day = "7",
doi = "10.1016/j.celrep.2017.10.059",
language = "English (US)",
volume = "21",
pages = "1588--1599",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action

AU - Chen, Jinling

AU - Liang, Yuejin

AU - Yi, Panpan

AU - Xu, Lanman

AU - Hawkins, Hal K.

AU - Rossi, Shannan

AU - Soong, Lynn

AU - Cai, Jiyang

AU - Menon, Ramkumar

AU - Sun, Jiaren

PY - 2017/11/7

Y1 - 2017/11/7

N2 - Zika virus (ZIKV) infection during pregnancy in humans results in intrauterine growth restriction, spontaneous abortion, and microcephaly. Here, we found that fetus-derived type I interferon (IFN-I) signaling can enhance anti-ZIKV responses and provide clinical benefits to the fetus. Because IFN-λ shares signaling cascades and antiviral functions with IFN-I, we investigated the in vivo effects of IFN-λ in ZIKV-infected pregnant mice. IFN-λ administration during mid-pregnancy reduced ZIKV burden in maternal and fetal organs and alleviated placental injuries and fetal demise. In addition, prophylactic and therapeutic treatment of IFN-λ1 in a human trophoblast line, as well as in primary human amniotic epithelial cells, greatly reduced the ZIKV burden. Our data highlight IFN-λ1 as a potential therapeutic useful for women at risk for congenital Zika disease. Chen et al. find that fetus-derived IFN-I signaling contributes to anti-ZIKV responses. IFN-λ administration during mid-pregnancy promotes host defense and reduces disease severity. IFN-λ1 treatment upregulates MX1 expression and establishes an antiviral state, leading to reduced ZIKV replication or elimination.

AB - Zika virus (ZIKV) infection during pregnancy in humans results in intrauterine growth restriction, spontaneous abortion, and microcephaly. Here, we found that fetus-derived type I interferon (IFN-I) signaling can enhance anti-ZIKV responses and provide clinical benefits to the fetus. Because IFN-λ shares signaling cascades and antiviral functions with IFN-I, we investigated the in vivo effects of IFN-λ in ZIKV-infected pregnant mice. IFN-λ administration during mid-pregnancy reduced ZIKV burden in maternal and fetal organs and alleviated placental injuries and fetal demise. In addition, prophylactic and therapeutic treatment of IFN-λ1 in a human trophoblast line, as well as in primary human amniotic epithelial cells, greatly reduced the ZIKV burden. Our data highlight IFN-λ1 as a potential therapeutic useful for women at risk for congenital Zika disease. Chen et al. find that fetus-derived IFN-I signaling contributes to anti-ZIKV responses. IFN-λ administration during mid-pregnancy promotes host defense and reduces disease severity. IFN-λ1 treatment upregulates MX1 expression and establishes an antiviral state, leading to reduced ZIKV replication or elimination.

KW - animal model

KW - antiviral

KW - congenital infection

KW - gestational stage

KW - human pregnancy

KW - interferon-λ

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85034087851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034087851&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2017.10.059

DO - 10.1016/j.celrep.2017.10.059

M3 - Article

VL - 21

SP - 1588

EP - 1599

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 6

ER -